Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Reports Third Quarter 2018 Financial Results
CINGAL Drives Strong International Viscosupplement Revenue Growth Achieves Solid Bottom Line Performance with $0.53 Diluted EPS BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing
View HTML
Toggle Summary Susan Vogt Appointed to Board of Directors of Anika Therapeutics
Long-Serving Director Steven Wheeler to Retire from Board in February 2019 BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on
View HTML
Toggle Summary Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 10, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day,
View HTML
Toggle Summary Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that
View HTML
Toggle Summary Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief
View HTML
Toggle Summary Anika Reports Second Quarter 2018 Financial Results
Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS New Leadership Added to Optimize Commercial Reach and Operating Efficiency Multiple Initiatives Ongoing to Gain U.S. Regulatory Approval of CINGAL BEDFORD, Mass. --(BUSINESS WIRE)--Jul.
View HTML
Toggle Summary Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July
View HTML
Toggle Summary Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis
CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant results of
View HTML
Toggle Summary Anika Therapeutics Announces $30 Million Accelerated Share Repurchase
BEDFORD, Mass. --(BUSINESS WIRE)--May 23, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that it will enter into an
View HTML
Toggle Summary Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress
BEDFORD, Mass. --(BUSINESS WIRE)--May 8, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced plans to showcase its innovative
View HTML